Navigation Links
AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs
Date:7/23/2008

WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- More than a third of the people who contacted AstraZeneca (NYSE: AZN) to inquire about the company's prescription savings programs learned of the programs from their doctors or pharmacists, according to a year-long survey of more than 12,000 patients.

The survey found that 35 percent of the patients who called AstraZeneca's information center regarding prescription savings programs said they were referred by healthcare professionals. Another 14 percent learned of the program from brochures, which also are available in doctors' offices, hospitals, clinics and pharmacies.

"AstraZeneca understands that our medicines don't do patients any good if they cannot afford to pay for them," said Tony Zook, President and CEO, AstraZeneca North America. "We connect families with our patient assistance programs in a variety of ways, but our most valuable tool is providing doctors and pharmacists with the information they need to help their patients."

As they meet with healthcare providers, AstraZeneca's pharmaceutical sales specialists share up-to-date clinical information on medicines and other issues impacting patient care, including adherence, educational materials and prescription savings programs.

The study's data shows that the message on patient assistance programs is getting through in a variety of ways. AstraZeneca asked 12,487 patients who contacted its information center between April 2007 and March 2008 where they learned about the company's patient assistance programs. The results:

-- Doctor/pharmacist 35 percent

-- Brochure 14 percent

-- Advertising 9 percent

-- AZ Web sites 7 percent

-- Community programs 6 percent

-- Family/friend 5 percent

-- Other/don't know 24 percent

Patients who cited advertising said they learned of the program from a variety of newspaper, radio and television ads. AstraZeneca was the first in the industry to promote its prescription savings programs in its product television ads. Television ads for NEXIUM started carrying the message in April 2005, and all of AstraZeneca's product television ads have included the information since then. Previous research shows that including this information in our advertising significantly raised awareness and the impact of AstraZeneca's patient assistance program among the public.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and now offers one of the industry's most generous programs. People without insurance who earn up to $30,000 for an individual and $60,000 for a family of four may be eligible for help from AstraZeneca.

In 2007 alone, AstraZeneca helped nearly half a million people fill 2.8 million prescriptions, resulting in more than $500 million of savings to patients. AstraZeneca offers help under the AZ&Me Prescription Savings programs, including support for people without insurance, people with Medicare Part D and a third program that provides medicines to healthcare facilities.

Patients can learn more about the AZ&Me Prescription Savings program at http://www.azandme.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit http://www.astrazeneca-us.com .


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
4. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
5. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
6. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
7. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
10. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... ended the trading session at 5,817.69, down 0.07%; the ... at 20,656.58; and the S&P 500 closed at 2,345.96, ... as 4 sectors closed in green, 4 sectors finished ... day. This Friday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... San Diego, Calif. (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to ... in 2008, it has hosted corporate cooking challenges for companies around the world, such as ... , Part of the reason for its increasing popularity is due to its new ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains ... strain on health care systems, in terms of costs and ... too does the development of innovative and efficient therapies that ... the many types of cancer treatments, a growing number of ...
Breaking Biology Technology:
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
(Date:3/2/2017)... LONDON , March 2, 2017 Who ... infringement lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... ON THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
Breaking Biology News(10 mins):